High-Resolution Melting (HRM) Analysis of Urinary DNA Methylation for Early Stage Bladder Cancer Diagnosis
Issued Date
2026-05-11
Resource Type
Scopus ID
2-s2.0-105039886125
Journal Title
Icbbe 2025 Proceedings of 2025 12th International Conference on Biomedical and Bioinformatics Engineering
Start Page
96
End Page
100
Rights Holder(s)
SCOPUS
Bibliographic Citation
Icbbe 2025 Proceedings of 2025 12th International Conference on Biomedical and Bioinformatics Engineering (2026) , 96-100
Suggested Citation
Lin N.A., Aroonsrimorakot S., Jarupan N., Palpai W., Honglertsakul C., Athamanolap P. High-Resolution Melting (HRM) Analysis of Urinary DNA Methylation for Early Stage Bladder Cancer Diagnosis. Icbbe 2025 Proceedings of 2025 12th International Conference on Biomedical and Bioinformatics Engineering (2026) , 96-100. 100. doi:10.1145/3794209.3794227 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/117045
Title
High-Resolution Melting (HRM) Analysis of Urinary DNA Methylation for Early Stage Bladder Cancer Diagnosis
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Bladder cancer (BC) requires early detection for improved patient outcomes. Traditional methods like cystoscopy and cytology are invasive, costly, and have limited sensitivity, especially in early-stage disease. This study assessed a non-invasive, urine-based approach using cell-free DNA (cfDNA) and high-resolution melting (HRM) analysis to detect DNA methylation at POU4F2 and ZNF671 biomarker loci. Urine samples from eight BC patients and seven healthy controls were analyzed. The methylation profiles showed distinct differences, with both markers achieving 87.5% sensitivity, 85.7% specificity, and 86.7% accuracy. Combined, the two-gene panel showed similar diagnostic performance. HRM-based profiling offers a rapid, cost-effective, and scalable method for non-invasive bladder cancer screening, diagnosis, and surveillance, requiring validation in larger studies.